Cowen analyst Steve Scala raised the firm’s price target on Eli Lilly to $430 from $390 and keeps an Outperform rating on the shares. The analyst said any weakness on the guidance would be a buying opportunity as the company is well positioned fundamentally and has a long history of beating expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- 3 Analyst-Loved Healthcare Stocks for a Recession
- Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
- Eli Lilly’s (NYSE:LLY) COVID-19 Therapy Loses FDA Authorization
- Eli Lilly says donanemab met all primary, secondary endpoints in Phase 3 study
- Bebtelovimab losing EUA has ‘limited impact’ on Piper model for AbCellera